197 related articles for article (PubMed ID: 32817060)
1. Real-world clinical outcome and toxicity data and economic aspects in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy: the experience of the Hellenic Cooperative Oncology Group.
Fountzilas E; Koliou GA; Vozikis A; Rapti V; Nikolakopoulos A; Boutis A; Christopoulou A; Kontogiorgos I; Karageorgopoulou S; Lalla E; Tryfonopoulos D; Boukovinas I; Rapti C; Nikolaidi A; Karteri S; Moirogiorgou E; Binas I; Mauri D; Aravantinos G; Zagouri F; Saridaki Z; Psyrri A; Bafaloukos D; Koumarianou A; Res E; Linardou H; Mountzios G; Razis E; Fountzilas G; Koumakis G
ESMO Open; 2020 Aug; 5(4):. PubMed ID: 32817060
[TBL] [Abstract][Full Text] [Related]
2. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
[TBL] [Abstract][Full Text] [Related]
3. Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis.
Gao JJ; Cheng J; Prowell TM; Bloomquist E; Tang S; Wedam SB; Royce M; Krol D; Osgood C; Ison G; Sridhara R; Pazdur R; Beaver JA; Amiri-Kordestani L
Lancet Oncol; 2021 Nov; 22(11):1573-1581. PubMed ID: 34656225
[TBL] [Abstract][Full Text] [Related]
4. First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study.
Basile D; Gerratana L; Corvaja C; Pelizzari G; Franceschin G; Bertoli E; Palmero L; Zara D; Alberti M; Buriolla S; Da Ros L; Bonotto M; Mansutti M; Spazzapan S; Cinausero M; Minisini AM; Fasola G; Puglisi F
Breast; 2021 Jun; 57():104-112. PubMed ID: 33812267
[TBL] [Abstract][Full Text] [Related]
5. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis.
Li J; Huo X; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
JAMA Netw Open; 2020 Oct; 3(10):e2020312. PubMed ID: 33048129
[TBL] [Abstract][Full Text] [Related]
6. Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: study protocol for a randomized controlled trial.
van Ommen-Nijhof A; Konings IR; van Zeijl CJJ; Uyl-de Groot CA; van der Noort V; Jager A; Sonke GS;
BMC Cancer; 2018 Nov; 18(1):1146. PubMed ID: 30458732
[TBL] [Abstract][Full Text] [Related]
7. Predictors of systemic therapy sequences following a CDK 4/6 inhibitor-based regimen in post-menopausal women with hormone receptor positive, HEGFR-2 negative metastatic breast cancer.
Princic N; Aizer A; Tang DH; Smith DM; Johnson W; Bardia A
Curr Med Res Opin; 2019 Jan; 35(1):73-80. PubMed ID: 30175631
[No Abstract] [Full Text] [Related]
8. Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
Li J; Fu F; Yu L; Huang M; Lin Y; Mei Q; Lv J; Wang C
Breast Cancer Res Treat; 2020 Feb; 180(1):21-32. PubMed ID: 31970560
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy.
Karacin C; Oksuzoglu B; Demirci A; Keskinkılıç M; Baytemür NK; Yılmaz F; Selvi O; Erdem D; Avşar E; Paksoy N; Demir N; Göksu SS; Türker S; Bayram E; Çelebi A; Yılmaz H; Kuzu ÖF; Kahraman S; Gökmen İ; Sakin A; Alkan A; Nayır E; Uğraklı M; Acar Ö; Ertürk İ; Demir H; Aslan F; Sönmez Ö; Korkmaz T; Celayir ÖM; Karadağ İ; Kayıkçıoğlu E; Şakalar T; Öktem İN; Eren T; Erul E; Mocan EE; Kalkan Z; Yıldırım N; Ergün Y; Akagündüz B; Karakaya S; Kut E; Teker F; Demirel BÇ; Karaboyun K; Almuradova E; Ünal OÜ; Oyman A; Işık D; Okutur K; Öztosun B; Gülbağcı BB; Kalender ME; Şahin E; Seyyar M; Özdemir Ö; Selçukbiricik F; Kanıtez M; Dede İ; Gümüş M; Gökmen E; Yaren A; Menekşe S; Ebinç S; Aksoy S; İmamoğlu Gİ; Altınbaş M; Çetin B; Uluç BO; Er Ö; Karadurmuş N; Erdoğan AP; Artaç M; Tanrıverdi Ö; Çiçin İ; Şendur MAN; Oktay E; Bayoğlu İV; Paydaş S; Aydıner A; Salim DK; Geredeli Ç; Yavuzşen T; Doğan M; Hacıbekiroğlu İ
BMC Cancer; 2023 Feb; 23(1):136. PubMed ID: 36765293
[TBL] [Abstract][Full Text] [Related]
10. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
Loibl S; Turner NC; Ro J; Cristofanilli M; Iwata H; Im SA; Masuda N; Loi S; André F; Harbeck N; Verma S; Folkerd E; Puyana Theall K; Hoffman J; Zhang K; Bartlett CH; Dowsett M
Oncologist; 2017 Sep; 22(9):1028-1038. PubMed ID: 28652278
[TBL] [Abstract][Full Text] [Related]
11. Real-world clinical outcomes and toxicity in metastatic breast cancer patients treated with palbociclib and endocrine therapy.
Varella L; Eziokwu AS; Jia X; Kruse M; Moore HCF; Budd GT; Abraham J; Montero AJ
Breast Cancer Res Treat; 2019 Jul; 176(2):429-434. PubMed ID: 30895534
[TBL] [Abstract][Full Text] [Related]
12. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
Tripathy D; Im SA; Colleoni M; Franke F; Bardia A; Harbeck N; Hurvitz SA; Chow L; Sohn J; Lee KS; Campos-Gomez S; Villanueva Vazquez R; Jung KH; Babu KG; Wheatley-Price P; De Laurentiis M; Im YH; Kuemmel S; El-Saghir N; Liu MC; Carlson G; Hughes G; Diaz-Padilla I; Germa C; Hirawat S; Lu YS
Lancet Oncol; 2018 Jul; 19(7):904-915. PubMed ID: 29804902
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of selective cyclin-dependent kinases 4/6 inhibitors in hormone-receptor-positive, HER2-negative advanced breast cancer - results from a real-world setting.
KovaČ A; Matos E; Kuhar CG; Čakš M; Ovčariček T; Mencinger M; Humar M; Borštnar S
Cancer Treat Res Commun; 2020; 25():100201. PubMed ID: 32979704
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes of tucidinostat-based therapy after prior CDK4/6 inhibitor progression in hormone receptor-positive heavily pretreated metastatic breast cancer.
Zhou J; Wu X; Zhang H; Wang X; Yuan Y; Zhang S; Jiang Z; Wang T
Breast; 2022 Dec; 66():255-261. PubMed ID: 36375386
[TBL] [Abstract][Full Text] [Related]
15. Real-World Evaluation of Disease Progression After CDK 4/6 Inhibitor Therapy in Patients With Hormone Receptor-Positive Metastatic Breast Cancer.
West MT; Goodyear SM; Hobbs EA; Kaempf A; Kartika T; Ribkoff J; Chun B; Mitri ZI
Oncologist; 2023 Aug; 28(8):682-690. PubMed ID: 36946994
[TBL] [Abstract][Full Text] [Related]
16. Combination cyclin-dependent kinase 4/6 inhibitors and endocrine therapy versus endocrine monotherapy for hormonal receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: A systematic review and meta-analysis.
Zheng J; Wu J; Wang C; Zhuang S; Chen J; Ye F
PLoS One; 2020; 15(6):e0233571. PubMed ID: 32497134
[TBL] [Abstract][Full Text] [Related]
17. Systemic Therapies Following Progression on First-line CDK4/6-inhibitor Treatment: Analysis of Real-world Data.
Martin JM; Handorf EA; Montero AJ; Goldstein LJ
Oncologist; 2022 Jun; 27(6):441-446. PubMed ID: 35552450
[TBL] [Abstract][Full Text] [Related]
18. Elective Discontinuation of CDK4/6 Inhibitors in Patients with Metastatic Hormone Receptor-Positive, Her-2-Negative Breast Cancer: A Retrospective Single-Center Experience.
Decker T; Seifert R; Bichler M; Birtel A; Fischer G; Nonnenbroich C; Dechow T
Oncol Res Treat; 2021; 44(9):443-449. PubMed ID: 34350900
[TBL] [Abstract][Full Text] [Related]
19. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
Cersosimo RJ
Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of Older Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer Treated With a CDK4/6 Inhibitor and an Aromatase Inhibitor: An FDA Pooled Analysis.
Howie LJ; Singh H; Bloomquist E; Wedam S; Amiri-Kordestani L; Tang S; Sridhara R; Sanchez J; Prowell TM; Kluetz PG; King-Kallimanis BL; Gao JJ; Ibrahim A; Goldberg KB; Theoret M; Pazdur R; Beaver JA
J Clin Oncol; 2019 Dec; 37(36):3475-3483. PubMed ID: 31560580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]